Kidney Transplant: Belatacept vs. Traditional Immunosuppressants

We are studying if replacing standard medications with belatacept helps kidney transplant patients with early graft dysfunction. The goal is to see if this approach improves kidney function and reduces rejection risks.

1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInjectionNephrology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Nulojix
Nulojix is a medicine used to help prevent organ rejection in people who have received a kidney transplant.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Belatacept
Belatacept is a substance that suppresses the immune response to help prevent rejection of transplanted organs, especially kidney transplants.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Nantes
Nephrology
Nantes, France
Sponsor: Centre Hospitalier Universitaire De Nantes
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.